8-K: Glucotrack Secures $20M Equity Line with Sixth Borough Capital

Glucotrack, Inc. entered into a purchase agreement with Sixth Borough Capital Fund, LP for up to $20 million in common stock, providing flexible capital over 24 months.

Summary

• Glucotrack, Inc. (GCTK) has entered into a Purchase Agreement and a Registration Rights Agreement with Sixth Borough Capital Fund, LP on September 11, 2025.
• The agreement allows Glucotrack to sell up to $20.0 million of its common stock to Sixth Borough Capital over a 24-month period, at the company's sole discretion, starting from the Commencement Date.
• Regular purchases will be priced at the lesser of 97% of the volume-weighted average price (VWAP) on the purchase date or the average of the three lowest closing prices in the prior ten trading days.
• Add-on and intraday purchases are also permitted under specific volume and pricing conditions, generally at a 95% discount to VWAP or lowest transaction price.
• A commitment fee of 1.5% of the $20.0 million total commitment ($300,000) is payable to Sixth Borough Capital, in cash, common stock, or pre-funded warrants, and is fully earned on the Commencement Date.
• The company intends to use the net proceeds from these sales for working capital and general corporate purposes.
• Glucotrack is obligated to file a registration statement (Form S-1) within 15 calendar days to cover the resale of shares issued to the investor and use best efforts to have it declared effective within 45 days.
• An 'Exchange Cap' limits the aggregate number of shares sold to 179,792 (19.99% of outstanding shares prior to the agreement) unless stockholder approval is obtained or the average price meets certain conditions.
• Sixth Borough Capital is restricted from short selling or hedging Glucotrack's common stock during the agreement term.
• Dawson James Securities, Inc. will receive a 1.5% cash fee on gross proceeds from sales to the investor.

Sentiment

Score: 6

Explanation: The agreement provides Glucotrack with a flexible source of capital, which is positive for its liquidity and ability to fund operations. However, the inherent dilution from selling shares at a discount and the associated fees (commitment fee, Dawson James fee) represent a cost to existing shareholders. The 'at-the-market' nature allows the company to manage dilution, but the 'Exchange Cap' and beneficial ownership limits could constrain the full utilization of the facility without further shareholder action. Overall, it's a necessary but not exceptionally favorable financing for a growth company.

Positives

• Secures access to up to $20.0 million in capital, providing financial flexibility for working capital and general corporate purposes over a 24-month period.
• The company retains discretion over the timing and amount of share sales, allowing it to manage dilution and market impact strategically.
• The investor is prohibited from engaging in short sales or hedging transactions establishing a net short position, which could help mitigate downward pressure on the stock price.
• The agreement imposes no restrictions on future financings, rights of first refusal, or participation rights, except for a specific prohibition on variable equity transactions without investor approval (excluding a future at-the-market offering with Dawson James).

Negatives

• The sale of common stock at a discount (97% for regular purchases, 95% for add-on/intraday purchases) will result in dilution for existing shareholders.
• A commitment fee of 1.5% ($300,000) is payable to the investor, reducing the net proceeds available to the company.
• An additional 1.5% cash fee is payable to Dawson James Securities, Inc. on gross proceeds, further reducing net capital.
• The 'Exchange Cap' limits the initial amount of shares that can be sold without stockholder approval, potentially delaying or limiting the full utilization of the $20.0 million facility.
• The investor's beneficial ownership is capped at 4.99%, which could limit the size of individual purchases if the investor approaches this threshold.
• The company is restricted from entering into other variable, reset, or adjustable equity or equity-linked transactions without the investor's prior written approval, potentially limiting future financing options.

Risks

• Dilution Risk: The issuance of new common stock to the investor will dilute the ownership percentage of existing shareholders.
• Market Price Volatility: The actual net proceeds received by the company will vary based on the trading price of the common stock and the frequency of sales, exposing the company to market volatility.
• Regulatory Compliance Risk: Failure to obtain stockholder approval for sales exceeding the 'Exchange Cap' could limit the company's ability to raise the full $20.0 million.
• Registration Statement Effectiveness Risk: The investor's obligation to purchase shares is contingent on the effectiveness of a registration statement, and any delays or stop orders could impact the company's access to capital.
• Liquidity Risk: If the company fails to electronically transfer shares (DWAC Shares) promptly, it may incur costs to cover the investor's sales or face other liabilities.
• Financing Restrictions: The prohibition on certain types of equity or equity-linked transactions without investor approval could limit the company's flexibility in seeking alternative financing.

Future Outlook

The company intends to use the net proceeds from the equity sales for working capital and general corporate purposes, supporting its ongoing operations and strategic initiatives over the next two years. The ability to draw capital at its discretion provides a flexible funding source, contingent on market conditions and the company's stock price.

Management Comments

• The Company currently intends to use any proceeds from such sales for working capital and general corporate purposes.
• The Company will control the timing and amount of any sales of Common Stock to the Investor pursuant to the Purchase Agreement.
• The actual amount and timing of any sales of Common Stock will be determined by the Company at its discretion and will depend on various factors, including, among others, general market conditions, the trading price of the Common Stock, and the Company’s assessment of appropriate funding sources for its operations.

Industry Context

This financing arrangement provides Glucotrack, a company likely in the healthcare technology or medical device sector (given its name), with a flexible funding mechanism. Such 'at-the-market' or equity line facilities are common for smaller, growth-oriented companies, particularly in sectors requiring significant R&D or market penetration investments, where traditional debt financing might be less accessible or more expensive. The structure allows the company to tap into capital as needed, minimizing immediate dilution, but also exposes it to market price fluctuations over time.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will experience dilution as new shares are issued at a discount to market price. The value of their existing holdings may be impacted by the timing and volume of sales.
• Company Operations: Benefits from enhanced liquidity and capital for working capital and general corporate purposes, supporting ongoing operations and potential growth initiatives.
• Investor (Sixth Borough Capital Fund, LP): Gains the opportunity to purchase shares at a discount, with potential for profit from resale, while being restricted from short-selling.
• Dawson James Securities, Inc.: Will receive a 1.5% cash fee on gross proceeds from sales, benefiting from the transaction.

Next Steps

• Company to file a Current Report on Form 8-K with the SEC within the required timeframe.
• Company to file a registration statement (Form S-1) with the SEC within 15 calendar days from September 11, 2025, covering the resale of shares.
• Company to use reasonable best efforts to have the registration statement declared effective within 45 days of filing.
• Company to secure additional listing of all Purchase Shares and Commitment Shares on the Principal Market.
• Company to obtain stockholder approval for the issuance of shares exceeding the Exchange Cap, if necessary, by November 6, 2025.
• Company to draw down capital from the facility at its discretion over the next 24 months, subject to terms and conditions.

Key Dates

Recommendation

The equity line provides Glucotrack with much-needed capital flexibility, which is a positive for its operational runway and strategic execution. However, the inherent dilution from selling shares at a discount, coupled with the commitment and advisory fees, will weigh on shareholder value. The 'at-the-market' nature allows the company to manage the pace of dilution, but the 'Exchange Cap' and beneficial ownership limits introduce potential hurdles to fully accessing the committed capital. Given these factors, the financing is a necessary step for a growth company but does not fundamentally alter the investment thesis in a way that warrants a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and monitor the company's execution, utilization of funds, and progress towards profitability.

Keywords

Glucotrack, GCTK, Equity Financing, Capital Raise, Purchase Agreement, Sixth Borough Capital, Common Stock, Dilution, SEC Filing, 8-K, Healthcare Technology, Medical Devices